guest ::
| Home > Publications database > Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. > print |
| Home > Publications database > Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. > print |
| 001 | 130805 | ||
| 005 | 20240228145554.0 | ||
| 024 | 7 | _ | |a 10.1038/leu.2017.92 |2 doi |
| 024 | 7 | _ | |a pmid:28322237 |2 pmid |
| 024 | 7 | _ | |a 0887-6924 |2 ISSN |
| 024 | 7 | _ | |a 1476-5551 |2 ISSN |
| 024 | 7 | _ | |a altmetric:20917080 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-05883 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kayser, Sabine |0 P:(DE-He78)ce3cd0df5fbbdf8768f6f1cd543bce72 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. |
| 260 | _ | _ | |a Basingstoke |c 2017 |b Nature Publ. Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1525863094_13985 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Therapy-related acute promyelocytic leukemia (t-APL) is relatively rare, with limited data on outcome after treatment with arsenic trioxide (ATO) compared to standard intensive chemotherapy (CTX). We evaluated 103 adult t-APL patients undergoing treatment with all-trans retinoic acid (ATRA) alone (n=7) or in combination with ATO (n=24), CTX (n=53), or both (n=19). Complete remissions were achieved after induction therapy in 57% with ATRA, 100% with ATO/ATRA, 78% with CTX/ATRA, and 95% with CTX/ATO/ATRA. Early death rates were 43% for ATRA, 0% for ATO/ATRA, 12% for CTX/ATRA and 5% for CTX/ATO/ATRA. Three patients relapsed, two developed therapy-related acute myeloid leukemia and 13 died in remission including seven patients with recurrence of the prior malignancy. Median follow-up for survival was 3.7 years. None of the patients treated with ATRA alone survived beyond one year. Event-free survival was significantly higher after ATO-based therapy (95%, 95% CI, 82-99%) as compared to CTX/ATRA (78%, 95% CI, 64-87%; P=0.042), if deaths due to recurrence of the prior malignancy were censored. The estimated 2-year overall survival in intensively treated patients was 88% (95% CI, 80-93%) without difference according to treatment (P=0.47). ATO when added to ATRA or CTX/ATRA is feasible and leads to better outcomes as compared to CTX/ATRA in t-APL. |
| 536 | _ | _ | |a 317 - Translational cancer research (POF3-317) |0 G:(DE-HGF)POF3-317 |c POF3-317 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Krzykalla, J. |0 P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9 |b 1 |u dkfz |
| 700 | 1 | _ | |a Elliott, M. A. |b 2 |
| 700 | 1 | _ | |a Norsworthy, K. |b 3 |
| 700 | 1 | _ | |a Gonzales, P. |b 4 |
| 700 | 1 | _ | |a Hills, R. K. |b 5 |
| 700 | 1 | _ | |a Baer, M. R. |b 6 |
| 700 | 1 | _ | |a Ráčil, Z. |b 7 |
| 700 | 1 | _ | |a Mayer, J. |b 8 |
| 700 | 1 | _ | |a Novak, J. |b 9 |
| 700 | 1 | _ | |a Žák, P. |b 10 |
| 700 | 1 | _ | |a Szotkowski, T. |b 11 |
| 700 | 1 | _ | |a Grimwade, D. |b 12 |
| 700 | 1 | _ | |a Russell, N. H. |b 13 |
| 700 | 1 | _ | |a Walter, R. B. |b 14 |
| 700 | 1 | _ | |a Estey, E. H. |b 15 |
| 700 | 1 | _ | |a Westermann, J. |b 16 |
| 700 | 1 | _ | |a Görner, M. |b 17 |
| 700 | 1 | _ | |a Benner, A. |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 18 |u dkfz |
| 700 | 1 | _ | |a Krämer, A. |0 P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0 |b 19 |u dkfz |
| 700 | 1 | _ | |a Smith, B. D. |b 20 |
| 700 | 1 | _ | |a Burnett, A. K. |b 21 |
| 700 | 1 | _ | |a Thiede, C. |b 22 |
| 700 | 1 | _ | |a Röllig, C. |b 23 |
| 700 | 1 | _ | |a Ho, A. D. |b 24 |
| 700 | 1 | _ | |a Ehninger, G. |b 25 |
| 700 | 1 | _ | |a Schlenk, Richard |0 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc |b 26 |u dkfz |
| 700 | 1 | _ | |a Tallman, M. S. |b 27 |
| 700 | 1 | _ | |a Levis, M. J. |b 28 |
| 700 | 1 | _ | |a Platzbecker, U. |b 29 |
| 773 | _ | _ | |a 10.1038/leu.2017.92 |g Vol. 31, no. 11, p. 2347 - 2354 |0 PERI:(DE-600)2008023-2 |n 11 |p 2347 - 2354 |t Leukemia |v 31 |y 2017 |x 1476-5551 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:130805 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)ce3cd0df5fbbdf8768f6f1cd543bce72 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 26 |6 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-317 |2 G:(DE-HGF)POF3-300 |v Translational cancer research |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b LEUKEMIA : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b LEUKEMIA : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)G330-20160331 |k G330 |l KKE Molekulare Hämatologie/Onkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)G040-20160331 |k G040 |l Klinische Studienzentrale |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)G330-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G040-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|